Company: INKT
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001193125-25-272532
Chunk: 7

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3
Chunk 7
---
.

Our approach
includes the development of both native and engineered iNKT cell therapies. Our pipeline includes wholly owned and exclusively licensed assets targeting solid tumors, pulmonary immune failure, and immune-related disorders. We have also developed a
proprietary neoantigen library that supports personalized TCR development by identifying patient-specific tumor signatures. These insights can be used to create highly tailored TCR-iNKT therapies, enabling
precision targeting across cancers and complex immune pathologies.

Our lead product candidate,
agenT-797, is an allogeneic, native iNKT cell therapy in development for both oncology and immune-mediated diseases. In a clinical trial (NCT05108623) involving patients with treatment-refractory solid tumors,
agenT-797 was evaluated as monotherapy and in combination with PD-1 inhibitors nivolumab or pembrolizumab. Treatment was associated with reductions in target and non-target lesions and durable disease stabilization, including a partial response in a patient with checkpoint-refractory gastric cancer. AgenT-797 also demonstrated
long-term persistence in the bloodstream—up to six months—without HLA matching or lymphodepletion. The therapy was well tolerated, with no cases of cytokine release syndrome (CRS) or GVHD.

These data were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in 2024. Preclinical data from the same program
demonstrated that agenT-797, when combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, or DLL3, enhanced tumor cell killing, T cell activation, and reduced exhaustion markers—supporting
potential future combination strategies.

Further peer-reviewed data support the clinical activity of
agenT-797. A case report published in Oncogene in January 2024 described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free
survival after a single infusion of agenT-797 plus nivolumab. More recently, on July 11, 2025, a landmark Oncogene publication reported a complete and durable remission in a patient with
metastatic, treatment-refractory testicular cancer. This patient, who had progressed on multiple prior therapies including chemotherapy, autologous stem cell transplant, and checkpoint blockade
(anti–PD-1, anti–CTLA-4, anti–TIGIT), received a single infusion of agen